港股异动 | 药品股高开 绿叶制药(2186.HK)高开逾8%
格隆汇8月29日丨药品股高开,绿叶制药(2186.HK)高开8.05%,李氏大药厂高开近4%,金嗓子高开逾2%,四环医药、白云山、国药控股高开逾1%。昨日晚间,绿叶制药公布中期业绩指,中期股东应占溢利同比增长36.2%至7.67亿元(人民币,下同);此前国药控股公布中期归母净利同比增加6.33%至29.75亿元。板块上,《国家基本医疗保险、工伤保险和生育保险药品目录》常规准入部分的药品名单已于20日挂网发布。初步确定128个药品纳入拟谈判准入范围,谈判成功的将被纳入目录。天风证券认为,相关纳入医保目录的品种将十分有望迎来放量,同时接下来的医保谈判目录将更加值得期待。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.